|
Jul 25
|
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
|
|
Jun 10
|
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
|
|
May 5
|
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
May 2
|
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
Apr 28
|
We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
|
|
Apr 11
|
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
|
|
Apr 8
|
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
|
|
Mar 28
|
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
|
|
Mar 6
|
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 5
|
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
|
|
Nov 30
|
Zymeworks Announces Participation in Upcoming Investor Conference
|
|
Nov 7
|
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|
|
Nov 1
|
Zymeworks Announces Participation in Upcoming Investor Conferences
|
|
Jun 26
|
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
|